1.15
Schlusskurs vom Vortag:
$1.12
Offen:
$1.13
24-Stunden-Volumen:
34,287
Relative Volume:
0.45
Marktkapitalisierung:
$10.02M
Einnahmen:
$6.74M
Nettoeinkommen (Verlust:
$-14.74M
KGV:
-0.5113
EPS:
-2.2491
Netto-Cashflow:
$-18.31M
1W Leistung:
+22.39%
1M Leistung:
+3.60%
6M Leistung:
-14.18%
1J Leistung:
-37.84%
Evogene Ltd Stock (EVGN) Company Profile
Vergleichen Sie EVGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
EVGN
Evogene Ltd
|
1.15 | 9.76M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-07-29 | Eingeleitet | Aegis Capital | Buy |
| 2020-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Eingeleitet | Oppenheimer | Outperform |
Evogene Ltd Aktie (EVGN) Neueste Nachrichten
Evogene (NASDAQ:EVGN) Stock Passes Below Fifty Day Moving Average – Time to Sell? - Defense World
Panic Selling: Will Evogene Ltd stock remain a Wall Street favorite2025 Price Targets & Low Drawdown Trading Strategies - moha.gov.vn
Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth - The Globe and Mail
Evogene appoints Dr. Olga Nissan as VP of business development By Investing.com - Investing.com Nigeria
Evogene appoints Nissan as VP of Business Development - TipRanks
Evogene appoints Dr. Olga Nissan as VP of business development - Investing.com
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development - Barchart.com
How Evogene Ltd. stock compares to industry benchmarks2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Will Evogene Ltd. stock remain a Wall Street favoriteQuarterly Growth Report & Smart Allocation Stock Reports - Bölüm Sonu Canavarı
Is Evogene Ltd. stock resilient to inflationJuly 2025 Setups & Free Daily Entry Point Trade Alerts - Улправда
Will Evogene Ltd. stock benefit from upcoming earnings reportsJuly 2025 Drop Watch & AI Based Trade Execution Alerts - DonanımHaber
Can Evogene Ltd. stock sustain market leadershipWeekly Gains Report & Safe Capital Investment Plans - DonanımHaber
Can Evogene Ltd. stock sustain free cash flow growth2025 Price Momentum & Entry and Exit Point Strategies - DonanımHaber
Should I hold or sell Evogene Ltd. stock in 20252025 Volume Leaders & Technical Buy Zone Confirmation - Улправда
Why Evogene Ltd. stock appeals to dividend seekersJuly 2025 Technicals & Weekly High Conviction Ideas - DonanımHaber
Is Evogene Ltd. stock attractive for growth ETFsBreakout Watch & Intraday High Probability Setup Alerts - Улправда
New Highs: How Evogene Ltd. stock compares to industry benchmarksVolume Spike & Consistent Return Strategy Ideas - Улправда
Will Evogene Ltd. stock keep outperforming rivalsWeekly Stock Recap & Growth Focused Investment Plans - Улправда
Reviewing Vera Therapeutics (NASDAQ:VERA) & Evogene (NASDAQ:EVGN) - Defense World
Will Introduced Innovation Sustain VLS Finance Limiteds GrowthInterest Rate Changes & Superior Trading Strategies - earlytimes.in
Investment Recap: Is Evogene Ltd stock a smart buy before Fed meetingTrade Entry Report & Free Growth Oriented Trading Recommendations - BỘ NỘI VỤ
Evogene (NASDAQ:EVGN) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
How AI Is Breaking Down the Bottlenecks in Small Molecule Drug Discovery - Unite.AI
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session - Sahm
Evogene (NASDAQ:EVGN) Share Price Passes Below Two Hundred Day Moving Average – What’s Next? - Defense World
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL (PR Newswire) - Aktiellt
Evogene shares climb 5% as cost reductions help deliver earnings beat - MSN
Evogene Ltd. Reports Strategic Shift and Financial Results - MSN
Evogene Ltd. Earnings Call: Strategic Shifts and Optimism - The Globe and Mail
Is Evogene Ltd. stock cheap compared to fundamentals - newser.com
Evogene Ltd. (NASDAQ:EVGN) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Evogene Ltd. stock hit record highs again2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Is Evogene Ltd. stock oversold or undervalued2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Evogene: Q3 Earnings Snapshot - Stamford Advocate
Evogene earnings beat by $0.12, revenue fell short of estimates - Investing.com Australia
Evogene Q3 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Evogene(EVGN.US) Q3 2025 Earnings Conference - 富途牛牛
Earnings call transcript: Evogene reports Q3 2025 earnings beat amid restructuring - Investing.com India
Evogene shares rise 5% as cost-cutting measures drive earnings beat - Investing.com Nigeria
Evogene Reports Third Quarter 2025 Financial Results - The AI Journal
Evogene Reports Q3 2025 Financial Results Amid Strategic Shift - TipRanks
Israeli biotech firm Evogene's Q3 revenue misses estimates due to reduced seed sales - TradingView
Evogene shares rise 5% as cost-cutting measures drive earnings beat By Investing.com - Investing.com South Africa
Evogene : Q3 2025 Consolidated Financial Statements - MarketScreener
Finanzdaten der Evogene Ltd-Aktie (EVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):